Om

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for the treatment of oncology and obesity. Its pipeline features TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor in Phase 1 clinical trials for chronic myeloid leukemia, a cancer originating in the bone marrow. The company also advances TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability, currently in Phase IIa trials for metabolic dysfunction-associated steatohepatitis. Terns Pharmaceuticals maintains a portfolio of single-agent and combination therapies targeting chronic liver diseases, including programs like an FXR agonist, a VAP-1 inhibitor, and a THR-β agonist. These efforts address significant unmet needs in areas such as non-alcoholic steatohepatitis and other metabolic conditions. Founded in 2017 and headquartered in Foster City, California, Terns Pharmaceuticals plays a key role in advancing innovative therapies within the biotechnology sector, emphasizing differentiated candidates for serious diseases.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I TERNS PHARMACEUTICALS MED ENDAVU: Køb Terns Pharmaceuticals ($430) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Terns Pharmaceuticals, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.